Categories
Uncategorized

Arthrosi Presents AR882 Posters at ACR 2021

Arthrosi Therapeutics, Inc., a clinical-stage biotech company announced results from its renal impairment studies and human AME study. The findings will be shared in two posters — “AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment” and “AR882, a Novel Uricosuric Agent, Exhibited Favorable Pharmacokinetic Profile and Balanced Excretion and Metabolic Pathways in a Human AME Study” — at the 2021 American College of Rheumatology Convergence. The world’s premier rheumatology experience will be held virtually from November 3-10, with more than 16,500 participants.

“The data is very promising for gout patients with various degrees of renal impairment,” said Arthrosi CEO Litain Yeh. “We’re looking forward to sharing the results of our study at this prestigious event.”

The Study
In subjects with various renal functions, a single dose of AR882 was found to produce mean serum urate levels (sUA) between 50 to 60 percent, regardless of mild, moderate impairment, or normal renal function. These results are consistent to those seen in previous phase 2a study where potent sUA lowering was also seen with gout patients with mild renal impairment in multiple doses. AR882 was well-tolerated in renal impaired subjects following single or multiple doses, showing a similar safety profile to that observed in healthy volunteer studies.

“Phase 2a and earlier studies with AR882 have shown it to be a promising new option for gout patients as a safe and potent urate lowering medication even in those with kidney impairment,” said Arthrosi’s Chief Medical Officer, Dr. Robert T. Keenan.

In addition, a human AME study showed a well-balance metabolic pathway of AR882 following a single oral dosing, with about 34 percent and 55 percent of AR882 excreted in urine and feces, respectively. At least 80 percent of AR882 is absorbed following oral administration. There is no human specific metabolites and AR882 was accounted for greater than 85% of radioactivity in circulation.

About Arthrosi
Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018 with a mission to create a revolutionary treatment option to target uric acid levels and reduce joint damage for people living with gout. With its vast therapeutic and treatment knowledge, Arthrosi has accumulated a comprehensive and robust intellectual property portfolio and impressive Phase 1 and Phase 2a data showing industry leading efficacy rates and superior safety profiles.

To learn more about Arthrosi, visit www.arthrosi.com

Media Contact:
Shunqi Yan, PhD
Founder & Chief Operating Officer
shunqi.yan@arthrosi.com

SOURCE Arthrosi Therapeutics

Categories
Uncategorized

Arthrosi Appoints Robert Thomas Keenan MD, MPH, MBA as Chief Medical Officer

Arthrosi Therapeutics, Inc. welcomes Robert Thomas Keenan, MD, MPH, MBA, as Chief Medical Officer. Dr. Keenan has spent nearly 20 years in the field of rheumatology, bringing his vast expertise to the team as they reach Phase2b in the clinical development of the next generation molecule for the treatment of gout.

“We are honored to welcome Dr. Robert Keenan to the Arthrosi team,” said Co-Founder and CEO Litain Yeh. “Dr. Keenan brings a significant amount of experience treating refractory gout, and as a key opinion leader in the field of rheumatology, he will help guide our future success.”

Prior to joining Arthrosi, Dr. Keenan spent most of his career at Duke University. Dr. Keenan was the Founding Director of the Gout and Crystal Arthropathy Clinic at Duke University Medical Center. During that time, he also held numerous roles, including Associate Chief Medical officer of the Patient Revenue Management Organization, Vice Chief for Clinical Affairs for the Division of Rheumatology, Medical Director of the Duke Specialty Infusion Center, and Associate Professor of Medicine at Duke University School of Medicine in the Division of Rheumatology and Immunology.

Dr. Keenan has also published several peer-reviewed articles and book chapters on gout. He obtained his undergraduate and Master of Public Health degree from the University of North Carolina at Chapel Hill, his Doctor of Medicine from St. George’s University School of Medicine, Master of Business Administration from the University of Massachusetts-Amherst and completed his Fellowship in Rheumatology at New York University.

“I am thrilled to join Arthrosi as Chief Medical Officer,” said Dr. Keenan. “I look forward to playing a key role in the development and commercialization of this revolutionary gout treatment that has the potential to truly solve the problem of gout by reducing uric acid levels and preventing joint damage.”

About Arthrosi

Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018 with a mission to create a revolutionary treatment option to target uric acid levels and reduce joint damage for people living with gout. With its vast therapeutic and treatment knowledge, Arthrosi has accumulated a comprehensive and robust intellectual property portfolio and impressive Phase 1 and Phase 2a data showing industry leading efficacy rates and superior safety profiles.

To learn more about Arthrosi, visit www.arthrosi.com

Media Contact:

Shunqi Yan, PhD
Founder & Chief Operating Officer
shunqi.yan@arthrosi.com

SOURCE Arthrosi Therapeutics

Categories
Uncategorized

Arthrosi Establishes Joint Venture in China to Accelerate Development of Innovative Drug Portfolio

Arthrosi Therapeutics, Inc. today announced a joint venture in Guangzhou China with Ruiao Biopharmaceutical Technology Co., Ltd. (“a subsidiary of  ApicHope  Phamaceutical”) to form Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

The joint venture will be responsible for the development of AR882 in the greater China area (Mainland China, Hong KongMacao, and Taiwan) while Arthrosi Therapeutics, Inc. continues to lead the global development of AR882 in the gout and tophaceous gout population.

In addition, the joint venture will allow Arthrosi to enter the precision medicine oncology therapeutic area by moving AR035, a potent EGFR exon 20 inhibitor targeting non-small cell lung cancer, into IND-enabling stage.

“We are enthusiastic about this opportunity to bring two drug development programs to the China market while collaborating with a leading Chinese pharmaceutical company with strong research, marketing, and sales capabilities. Partnering with ApicHope will accelerate the development of our two groundbreaking drugs in Western countries and in Asia,” said Litain Yeh, PhD, CEO of Arthrosi.

The registered joint venture is anticipated to result in a $34.3 million investment for development in the greater China area, and another $25 million to participate in Arthrosi Therapeutics Series-C equity financing.

“Through this outbound investment and the establishment of a joint venture in China, we will further enrich the company’s product pipeline, provide access to the global market rights of the product, and accelerate the company’s innovative drug portfolio in the field of innovative drugs,” said Hanxiong Li, an  Executive from ApicHope.

About Arthrosi

Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018 with a mission to create a revolutionary treatment option to target uric acid levels and reduce joint damage for people living with gout. With its vast therapeutic and treatment knowledge, Arthrosi has accumulated a comprehensive and robust intellectual property portfolio and impressive Phase 1 and Phase 2a data showing industry leading efficacy rates and superior safety profiles.

About ApicHope

ApicHope Pharmaceutical is an innovative pharmaceutical company with integrated R&D, manufacturing, sales, and distribution capability. It was founded in 2002 and listed on the Shenzhen Stock Exchange in November 2017 (300723.SZ). ApicHope is quality-driven with robust marketing and sales in chronic disease, anti-infectious disease, and pediatrics treatment. ApicHope has been expanding its R&D  into vaccine therapy, precision medicine toward oncology, and ophthalmic drugs.

To learn more about Arthrosi, visit www.arthrosi.com.

Media Contact:
Shunqi Yan, PhD
Founder & Chief Operating Officer
shunqi.yan@arthrosi.com

SOURCE Arthrosi Therapeutics

Categories
Uncategorized

Arthrosi Therapeutics, Inc. Announces Impressive Phase 2a Study Results

With AR882 showing strong efficacy and safety profile in Phase 2a study, Arthrosi is accelerating the development and looking to complete the Phase 2 studies by the middle of 2022.

SAN DIEGO, June 1, 2021 – Arthrosi Therapeutics, Inc. announced results from its Phase 2a study investigating the efficacy and safety of its potent urate lowering agent AR882. Arthrosi is transforming the U.S. gout therapeutic market with the first blockbuster-potential molecule to truly solve the problem of gout by reducing uric acid levels and preventing joint damage.

The Phase 2a study, which involved 30 patients with a history of gout with normal renal function or mild renal impairment, found AR882 to be the best-in-class urate lowering agent among in-development and marketed drugs, with the potential to treat all stages of gout.
Key findings included:

• Superiority response rates with 50 mg AR882 compared to other urate lowering agents, including allopurinol and febuxostat

• Stronger serum uric acid (sUA) lowering effects when using AR882 as a mono therapy than any oral agents commercially available

• Same potency among patients with normal renal function and patients with mild renal impairment

• Potential of flare lowering and tophi reduction in longer treatment

• Serum creatinine level was unaffected. There were no SAEs or AEs leading to study drug discontinuation, and no clinically significant trends in any laboratory or ECG parameters were noted. AR882 was well tolerated

“I am delighted with our trial findings that demonstrate AR882’s ability to help people with gout live better lives,” said CEO Litain Yeh. “With over 90% of patients seeing serum urate levels below 5 mg/dL at 50 mg dosing and below 4 mg/dL at 75 mg dosing, the results have exceeded our expectations in terms of safety and efficacy.”

The results will be presented at the upcoming 2021 annual European Congress of Rheumatology (EULAR) on June 2-5, 2021. To further expand the patient population, Arthrosi initiated a study of AR882 in subjects with different degrees of renal impairment and the results are expected to be presented at upcoming scientific meetings.

Given the strong efficacy and safety profile of AR882, Arthrosi is accelerating the development and is looking to complete the phase 2 studies by the middle of 2022. Arthrosi is currently raising Series C funding. Interested investors can reach out to investorrelations@arthrosi.com

About Arthrosi

Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018 with a mission to create a revolutionary treatment option to target uric acid levels and reduce joint damage for people living with gout. With its vast therapeutic and treatment knowledge, Arthrosi has accumulated a comprehensive and robust intellectual property portfolio and impressive Phase 1 and Phase 2a data showing industry leading efficacy rates and superior safety profiles.

To learn more about Arthrosi, visit www.arthrosi.com

Media Contact:
Shunqi Yan, PhD
Founder & Chief Operating Officer
shunqi.yan@arthrosi.com

SOURCE Arthrosi Therapeutics

Categories
Uncategorized

Arthrosi’s New Molecule AR882 for Gout Shows Blockbuster-Potential

Our mission is to eliminate the pain of gout with a new era of gout treatment that provides a true solution.

SAN DIEGO, May 10, 2021 – Arthrosi Therapeutics, Inc, a pharmaceutical company founded in 2018 by a team of well-established experts in drug development, announced the first blockbuster-potential molecule, AR882, to treat gout. It will be the first small molecule that exhibits the potential to demonstrate clinical benefits, such as shrinking tophi and reducing flares, through the mechanism of URAT1 inhibition based on its Phase 2a study.

Gout is a debilitating form of inflammatory arthritis affecting roughly 9 million people in the United States. The disease is caused by elevated levels of uric acid crystals in the joints, which can trigger painful and debilitating inflammation. If left untreated, gout can cause tophi, or large, visible bumps made of urate crystals that can cause permanent joint damage.

“A large percentage of the 9 million patients living with gout are undertreated, relying on short-term or sub-optimal treatments that don’t meet their needs,” said Co-Founder and CEO Litain Yeh. “Our mission is to eliminate the pain of gout with a new era of gout treatment that provides a true solution for removing uric acid in the body and preventing the development of tophi.”
After the completion of four clinically robust studies with more than 100 healthy volunteers and gout patients, AR882 has shown unmatched promise, with excellent renal safety profiles and industry-leading efficacy rates.

About Arthrosi
Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018 with a mission to create a revolutionary treatment option to target uric acid levels and reduce joint damage for people living with gout. With its vast therapeutic and treatment knowledge, Arthrosi has accumulated a comprehensive and robust intellectual property portfolio and impressive Phase 1 and Phase 2a data showing industry leading efficacy rates and superior safety profiles.

To learn more about Arthrosi, visit www.arthrosi.com.

Media Contact:
Shunqi Yan, PhD
Founder & Chief Operating Officer

shunqi.yan@arthrosi.com

SOURCE Arthrosi Therapeutics

Categories
Uncategorized

Arthrosi Expands Disease Expertise with New Board of Director Appointment

Arthrosi Therapeutics, Inc. today announced the appointment of James Mackay, PhD, to its board of directors.

SAN DIEGO, Apr 20, 2021 – Arthrosi Therapeutics, Inc. today announced the appointment of James Mackay, PhD, to its board of directors. Dr. Mackay brings more than 30 years of in-depth experience to the team, as they reach Phase2b in the clinical development of AR882, the next generation molecule for the treatment of gout.

“We are pleased to welcome Dr. Mackay to the Arthrosi board,” said Co-Founder and CEO Litain Yeh. “James brings a significant amount of experience, playing an instrumental role in the development and commercialization of the last two gout treatments. His experience, vision, and knowledge of the gout market will help guide our future success.”

From 2013 to 2018, Dr. Mackay was President and CEO of Ardea Biosciences, where he was instrumental in setting up an innovative company model that retained the biotech’s independence and accountability for the development of the gout franchise, including the subsequent FDA- and EMA-approved Zurampic and Duzallo, the first new mechanism of action treatments for gout in over 60 years. During his time, he also developed a synergistic and collaborative relationship with the parent company AstraZeneca.

In 2018, Dr. Mackay founded Aristea Therapeutics, an immunology focused company developing treatments for orphan diseases. He currently sits on the boards of BIOCOM and CONNECT, where he also serves as Chair. Dr. Mackay is also an independent board member of MatriSys Bioscience and Privo Technologies.

“I am thrilled to join the Arthrosi board to help prepare the market for this revolutionary gout treatment,” said Dr. Mackay. “Finally, there will be a solution that will address the excretion of uric acid and help the many people living with this extremely painful condition.”

About Arthrosi

Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018 with a mission to create a revolutionary treatment option to target uric acid levels and reduce joint damage for people living with gout. With its vast therapeutic and treatment knowledge, Arthrosi has accumulated a comprehensive and robust intellectual property portfolio and impressive Phase 1 and Phase 2a data showing industry leading efficacy rates and superior safety profiles.

To learn more about Arthrosi, visit www.arthrosi.com.
Media Contact:

Shunqi Yan, PhD
Founder & Chief Operating Officer
shunqi.yan@arthrosi.com

SOURCE Arthrosi Therapeutics